Dr. Gary Charles Rosenblum, DO

Dr. Rosenblum practices at Nassau University Medical Center in East Meadow, New York, part of NuHealth.

Dr. Rosenblum's NPI, 1194706556, was assigned on November 10, 2005. Dr. Rosenblum graduated from New York College of Osteo Medicine of New York Institute of Technology in 1987. Dr. Rosenblum holds New York license NYS176247.

Dr. Rosenblum's primary practice is Nassau University Medical Center, at 2201 Hempstead Turnpike, East Meadow, NY 11554 in Nassau County. The practice phone is (516) 572-0123.

Dr. Rosenblum's primary practice is Nassau University Medical Center in East Meadow, New York, part of NuHealth. Dr. Rosenblum is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Rosenblum to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account. Dr. Rosenblum's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosenblum practices, 4 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Rosenblum's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Rosenblum is licensed in New York.

CMS data shows 5,865 Medicare services from Dr. Rosenblum across 13 procedure codes in 2024, for 369 Medicare patients. Medicare paid $129,092 for them.

CMS counts 369 Medicare patients who saw Dr. Rosenblum in 2024. The largest group is 65 to 74, with 161 patients. 75% of them have arthritis, and 75% have high blood pressure. 14% are also on Medicaid. Their average risk score is 1.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosenblum's median patient age at 59, with 74% women.

In 2024, Dr. Rosenblum wrote 1,021 Medicare Part D claims for 210 patients. 82% of them were for generic drugs. CMS names the drug for 825 of them, across 20 drugs with 11 or more claims each, at $1,155,710 in total drug cost. In 2023, CMS named 842 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Rosenblum for performance year 2024, reported as part of a group. Dr. Rosenblum accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rosenblum as offering telehealth.

Dmand AI links 1 paper to Dr. Rosenblum in 2013. Dr. Rosenblum's most frequent co-authors are Elise Belilos, MD, Kristina Belostocki, MD and Steven Eric Carsons, MD.

CMS Open Payments shows 439 general payments to Dr. Rosenblum from 11 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 89% of the total. Abbvie Inc. paid the most, $196,996.

Dr. Rosenblum graduated from New York College of Osteo Medicine of New York Institute of Technology in 1987.